Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TTI-0102 for Mild to Moderate COVID-19
NCT05212662Phase 2Withdrawn
- Sponsor
- Thiogenesis Therapeutics
- Start
- Sep 2024
- Primary completion
- Sep 2024
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing TTI-0102 with Placebo (2 arms). Primary endpoint: Frequency of hospitalization or death at 28 days. Planned start Sep 2024; status: withdrawn.
02
Drugs
cysteamine-pantetheine disulfide
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05212662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05212662.